SixSigmaCapital (@sixsigmacapital): "NVO LLY Wegovy® pill demonstrated greater weight loss than orforglipron (Foundayo) and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026"

The app for independent voices

SixSigmaCapital: Navigating the Financial Markets

NVO LLY

Wegovy® pill demonstrated greater weight loss than orforglipron (Foundayo) and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026

Apr 2

at

1:23 PM

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts

The app for independent voices

Log in or sign up